Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn’s disease patients-Reference-Cited by-同舟云学术

Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn’s disease patients

Published:2024-06-21 Issue:4 Volume:24 Page:
ISSN:1470-269X
Container-title:The Pharmacogenomics Journal
language:en
Short-container-title:Pharmacogenomics J

Author:

Salazar Juliana^ORCID,Riera Pau^ORCID,Gordillo Jordi,Altès Albert^ORCID,Martínez Miguel^ORCID,Serès Montserrat,Llaó Jordina,Giordano Antonio^ORCID,Garcia-Planella Esther

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41397-024-00341-2.pdf

Reference30 articles.

1. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571–607. https://doi.org/10.1136/gut.2010.224154

2. Chatu S, Subramanian V, Saxena S, Pollok RC. The role of thiopurines in reducing the need for surgical resection in Crohn’s disease: a systematic review and meta-analysis. Am J Gastroenterol. 2012;107:23–34. https://doi.org/10.1038/ajg.2011.401

3. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2009;104:2089–96. https://doi.org/10.1038/ajg.2009.301

4. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95. https://doi.org/10.1056/NEJMoa0904492

5. Chaparro M, Panés J, García V, Mendoza JL, Bermejo F, López San Román A, et al. Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients. Inflamm Bowel Dis. 2013;19:1404–10. https://doi.org/10.1097/MIB.0b013e318281f28f